Medinol v. Boston Scientific
This article was originally published in The Gray Sheet
Executive Summary
Stent maker Medinol's ongoing suit against distributor Boston Scientific Chairman Pete Nicholas and CFO Larry Best will be allowed to proceed alongside other suits between the parties related to alleged supply agreement violations under a New York federal court ruling denying the execs' motion for dismissal. The court's action, which also dismissed personal claims against other Boston Scientific employees, comes three months after dismissal of similar claims against the individual managers of Medinol. Boston Scientific maintains the actions are preliminary and not expected to adversely impact the overall litigation. The New York proceedings are separate from ongoing shareholder rights litigation brought against Medinol in Israel by minority stakeholder Boston Scientific...
You may also be interested in...
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.
UK MHRA Updates Assistive Tech And Borderline Regulations
Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.
Fujifilm Demonstrates Health Specialism With European HealthTech Spinout
From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics.